HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.

Abstract
Resveratrol and celecoxib were used as chemopreventive agents in animal models of carcinogenesis, and exert antiproliferative and proapoptotic effects on cancer cells. Therefore, the aim of this study was to evaluate whether combining resveratrol with celecoxib may exert more potent anticarcinogenic effects than the single agents. Mammary carcinogenesis was initiated in 70 female Sprague-Dawley rats with N-methyl-N-nitrosourea (NMU). The chemoprevention with resveratrol, celecoxib, and their combination started 2 weeks before the first carcinogen dose and lasted until the end of the experiment. Tumor incidence and frequency, latency period, tumor volume, the expression of cyclooxygenase 2 (COX2) and growth differentiation factor 15 (GDF15), and also the formation of reactive oxygen species were analyzed using different methods. In addition, the levels of resveratrol and its metabolites in blood and selected tumor tissues were determined by high-performance liquid chromatography. Finally, the anticancer effects of the reagents were studied in the human breast cancer cell line MCF-7. Celecoxib as a single agent significantly decreased tumor frequency, prolonged tumor latency, and decreased the total number of malignant tumors compared with the NMU conditions. Tumor volume was nonsignificantly reduced (0.68±0.25 vs. 0.93±0.28 cm3). Importantly, the addition of resveratrol to celecoxib reduced tumor volume by 60% compared with celecoxib alone (from 0.68±0.25 to 0.27±0.07 cm3, P<0.05). Furthermore, the combination of resveratrol and celecoxib reduced tumor frequency by 29% compared with celecoxib alone (P=0.53). Tumor latency was not influenced by this combination compared with celecoxib alone (126.56±3.45 vs. 120.71±4.08 days). In addition, COX2 mRNA and immunoreactive protein stained on tumor sections were reduced and GDF15 protein increased significantly by the combination studied compared with the NMU conditions. In agreement with these data, a significant reduction in reactive oxygen species in blood lymphocytes of the combination was detected, which may have contributed toward the cancer-preventive effects of this application. This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters. In addition, in terms of tumor volume, the combination was more efficient than celecoxib as a single agent.
AuthorsTerézia Kisková, Rastislav Jendželovský, Erdenetsetsek Rentsen, Alexandra Maier-Salamon, Natália Kokošová, Zuzana Papčová, Jaromír Mikeš, Peter Orendáš, Bianka Bojková, Peter Kubatka, Martin Svoboda, Karol Kajo, Peter Fedoročko, Walter Jäger, Cem Ekmekcioglu, Monika Kassayová, Theresia Thalhammer
JournalEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) (Eur J Cancer Prev) Vol. 23 Issue 6 Pg. 506-13 (Nov 2014) ISSN: 1473-5709 [Electronic] England
PMID25254309 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anticarcinogenic Agents
  • Carcinogens
  • Pyrazoles
  • Stilbenes
  • Sulfonamides
  • Methylnitrosourea
  • Celecoxib
  • resveratrol
Topics
  • Animals
  • Anticarcinogenic Agents (pharmacology)
  • Breast Neoplasms (chemically induced, prevention & control)
  • Carcinogens
  • Celecoxib
  • Chemoprevention (methods)
  • Drug Synergism
  • Female
  • Humans
  • MCF-7 Cells
  • Mammary Neoplasms, Experimental (chemically induced, prevention & control)
  • Methylnitrosourea
  • Pyrazoles (administration & dosage, pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Stilbenes (administration & dosage, pharmacology)
  • Sulfonamides (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: